Genmab A/S (GNMSF) Total Current Liabilities (2019 - 2026)

Genmab A's (GNMSF) quarterly Total Current Liabilities came in at $1.2 billion in Q1 2026, down 17.45% on a QoQ basis from $1.4 billion in Q4 2025.

Genmab A/S (GNMSF) Total Current Liabilities (2019 - 2026) Analysis & Trends

Genmab A (GNMSF) has 6 years of Total Current Liabilities data on file, last reported at $1.2 billion in Q1 2026.

Quarterly Total Current Liabilities changed N/A year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (changed N/A YoY) and the FY2025 annual result came in at $1.4 billion, up 91.8% from the prior year.
Total Current Liabilities declined to $1.2 billion in Q1 2026, from $1.4 billion in the prior quarter.
In the past five years, Total Current Liabilities ranged from a high of $1.4 billion in Q4 2025 to a low of $368.0 million in Q4 2023.
A 4-year average of $847.8 million and a median of $742.5 million in 2024 frame the typical range for Total Current Liabilities.
Annual changes were most pronounced in 2024 — Total Current Liabilities surged 102.17% — and 2025, when it soared 91.8%.
Tracing GNMSF's Total Current Liabilities over 4 years: stood at $368.0 million in 2023, then surged by 102.17% to $744.0 million in 2024, then soared by 91.8% to $1.4 billion in 2025, then decreased by 17.45% to $1.2 billion in 2026.
The last three Total Current Liabilities figures came in at $1.2 billion (Q1 2026), $1.4 billion (Q4 2025), and $741.0 million (Q3 2025), per Business Quant data.

Download Data